Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

2.3K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.3K
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

493
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
493
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

367
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
367
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

605
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
605
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

523
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
523
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

991
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
991

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CDAI trajectories in patients with rheumatoid arthritis treated with abatacept in real-world.

Advances in rheumatology (London, England)·2026
Same author

Lessons from an early rheumatoid arthritis incident cohort.

Seminars in arthritis and rheumatism·2026
Same author

Evaluating machine learning tools to assist title and abstract screening in systematic literature reviews: a report based on the EULAR RA Management Recommendations Task Force.

Annals of the rheumatic diseases·2026
Same author

Racial minorities are under-represented in SLE clinical trials: A systematic review and meta-analysis.

Autoimmunity reviews·2026
Same author

Real-World Upadacitinib Persistence and Clinical Outcomes Among Canadian Patients with Inflammatory Arthritis from a Patient Support Program: The UPRAISE Study.

Rheumatology and therapy·2026
Same author

Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis.

Annals of the rheumatic diseases·2026

Related Experiment Video

Updated: Apr 16, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

19.1K

Treatment Algorithms in Systemic Lupus Erythematosus.

Chayawee Muangchan1, Ronald F van Vollenhoven2, Sasha R Bernatsky3

  • 1Siriraj Hospital, Mahidol University, Bangkok, Thailand, and University of Western Ontario, London, Ontario, Canada.

Arthritis Care & Research
|March 18, 2015
PubMed
Summary

Systemic lupus erythematosus (SLE) treatment guidelines show variable expert agreement. Experts reached consensus on several treatment approaches for various SLE manifestations, even without extensive clinical trial data.

More Related Videos

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.7K
Murine Bilateral Renal Lymphadenectomy
06:20

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

185

Related Experiment Videos

Last Updated: Apr 16, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

19.1K
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.7K
Murine Bilateral Renal Lymphadenectomy
06:20

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

185

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Systemic lupus erythematosus (SLE) is a complex autoimmune disease requiring nuanced treatment strategies.
  • Establishing consensus on optimal SLE management is crucial for improving patient outcomes.
  • Current treatment guidelines often lack definitive evidence for specific clinical scenarios.

Purpose of the Study:

  • To achieve expert consensus on preferred treatment algorithms for various manifestations of SLE.
  • To identify areas of agreement and disagreement among SLE specialists regarding therapeutic choices.
  • To inform clinical practice by providing evidence-based recommendations where data is limited.

Main Methods:

  • A Delphi-like method involving 69 SLE experts who responded to clinical scenarios via email.
  • Development of treatment algorithms based on expert-indicated preferences.
  • Determination of expert agreement using a threshold of ≥50% respondents indicating ≥70% agreement.

Main Results:

  • An initial response rate of 54% (37 experts) was achieved.
  • Agreement was established for 14 out of 16 scenarios, covering discoid lupus, cutaneous vasculitis, arthritis, pericarditis, interstitial lung disease, pulmonary hypertension, antiphospholipid antibody syndrome, neurological involvement, and lupus nephritis.
  • Specific treatment sequences were outlined, including first-line, second-line, and subsequent therapies, often involving agents like hydroxychloroquine, glucocorticoids, mycophenolate mofetil, azathioprine, cyclophosphamide, rituximab, and belimumab.

Conclusions:

  • Variable agreement exists among experts on SLE treatment strategies.
  • Consensus was achieved for several treatment decisions, highlighting areas where expert opinion can guide practice.
  • These findings provide valuable insights for managing SLE, particularly in situations lacking robust randomized controlled trial data.